Supernus Pharmaceuticals, Inc. (SUPN)
46.51
+0.35
(+0.76%)
USD |
NASDAQ |
Dec 11, 16:00
46.50
-0.02
(-0.03%)
After-Hours: 20:00
Supernus Pharmaceuticals Cash from Investing (Quarterly): 48.71M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Biogen, Inc. | -35.10M |
| BridgeBio Pharma, Inc. | 4.464M |
| CorMedix, Inc. | -291.32M |
| Assembly Biosciences, Inc. | -158.27M |
| Viking Therapeutics, Inc. | 160.02M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -61.66M |
| Cash from Financing (Quarterly) | 21.07M |
| Free Cash Flow | 70.75M |
| Free Cash Flow Per Share (Quarterly) | -1.093 |
| Free Cash Flow to Equity (Quarterly) | -72.23M |
| Free Cash Flow to Firm (Quarterly) | -61.79M |
| Free Cash Flow Yield | 2.70% |